Biogen Inc. (ETR:IDP)
Germany · Delayed Price · Currency is EUR | Market Cap | 21.80B |
| Revenue (ttm) | 8.58B |
| Net Income (ttm) | 1.37B |
| Shares Out | n/a |
| EPS (ttm) | 9.35 |
| PE Ratio | 15.90 |
| Forward PE | 13.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 187 |
| Average Volume | 765 |
| Open | 148.15 |
| Previous Close | 148.15 |
| Day's Range | 148.15 - 150.55 |
| 52-Week Range | 99.00 - 160.90 |
| Beta | 0.13 |
| RSI | 55.09 |
| Earnings Date | Feb 12, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
Biogen (BIIB) Set to Advance New Drug BIIB145 from Collaboration
Biogen (BIIB) Set to Advance New Drug BIIB145 from Collaboration
Eisai: "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
TOKYO and CAMBRIDGE, Mass., Dec 9, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
Nasdaq 100 Movers: BIIB, MSTR
In early trading on Tuesday, shares of Strategy topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.0%. Year to date, Strategy has lost about 42.3% of its val...
Nasdaq-100 Shake-Up: These 6 Stocks Are In, 6 Are Out — And It Could Trigger Big Moves
The Nasdaq-100 Index has announced its annual reconstitution, adding six new companies and removing six, effective Dec. 22. Six Stocks Added, Six Dropped From Index The six companies being added to th...
Biogen: Alzheimer's Disease Treatment Needs More Real-World Data
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions
Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others considered for additions. Read more here.
Biogen (BIIB) Sees Target Price Increase by Morgan Stanley | BIIB Stock News
Biogen (BIIB) Sees Target Price Increase by Morgan Stanley | BIIB Stock News
BIIB: Analyst Raises Price Target, Maintains Equal-Weight Rating | BIIB Stock News
BIIB: Analyst Raises Price Target, Maintains Equal-Weight Rating | BIIB Stock News
Biogen (BIIB) Downgraded by HSBC Amid Growth Concerns
Biogen (BIIB) Downgraded by HSBC Amid Growth Concerns
AbbVie upgraded, Biogen downgraded as HSBC reflects on 2026 in pharma
This Biogen Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
HSBC Downgrades Biogen (BIIB) with New Target Price | BIIB Stock News
HSBC Downgrades Biogen (BIIB) with New Target Price | BIIB Stock News
Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada
TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that Health Canada has issued a Notice of Compliance (NOC) for ZURZUVAE™ (zuranolone) for the treatment of moderate or severe postpartum de...
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
Eisai: New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
TOKYO and CAMBRIDGE, Mass., Dec 3, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
BIIB: Promising Data for Biogen's Zorevunersen in Dravet Syndrome Treatment
BIIB: Promising Data for Biogen's Zorevunersen in Dravet Syndrome Treatment
Biogen (BIIB) Advances Potential Treatment for Dravet Syndrome with Promising Data
Biogen (BIIB) Advances Potential Treatment for Dravet Syndrome with Promising Data
Stoke, Biogen Present Positive Long-Term Results For Zorevunersen In Dravet Syndrome
(RTTNews) - Stoke Therapeutics, Inc. (STOK) and Biogen Inc. (BIIB) on Friday reported positive long-term data from the Phase 1/2a and open-label extension studies evaluating zorevunersen in patients w...
Biogen Inc.: Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
-Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in se...
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizu...
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
BIIB January 2026 Options Begin Trading
Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options...
Eisai And Biogen Report Long-Term Benefits Of LEQEMBI In Early Alzheimer's Disease
(RTTNews) - Eisai Co., Ltd. and Biogen Inc. announced new findings on the continued and expanding benefit of LEQEMBI (lecanemab-irmb) maintenance treatment in early Alzheimer's disease at the 18th Cli...
Biogen (BIIB) Reports Promising Lecanemab Findings for Alzheimer's Treatment
Biogen (BIIB) Reports Promising Lecanemab Findings for Alzheimer's Treatment
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started tre...